Dr. Pavan Kumar

Aspiring for leadership roles where ample opportunity exists for ideation and innovation that brings value addition parallel to conventional stream of deliverables for overall growth of an organization and for sustaining the same on long term. Performance-driven Vice President with 20 plus years of experience aligning systems with business requirements, policies and regulatory requirements. Passionate about applying excellent organization and communication skills to manage and lead teams. Results-oriented individual well-versed in interfacing and consulting on business processes to drive results based on sound overall business judgment.

• Practical experience in ideation led working environment from concept to commercialization including fixed dose combinations
• Well versed with development of formulation by QbD concepts (QTPP, CQA, CMA, CPP, Identification of Risks and reduction of risks, Control Strategies, etc) for IR & MR dosage forms, activities related to technology transfer, execution of Exhibit & Commercial batches.
• Proven abilities in addressing deficiencies of different regulatory markets
• Handled and with proven abilities to work and lead teams in different dosage forms like OSD, Liquid dosage forms, topicals development right from inception of product design to filing including development, analysis and technology transfer domains. Handled and guided teams indirectly on injectable dosage forms including third party manufacturing scale
• Hands on experience with proven abilities for oral solids dosage forms and expertise on other forms such as semi solids, effervescent tablets, suppositories, injections.
• Handled projects and well versed in NDDS domain and include controlled release dosage forms, multi unit particulate systems, and has the ability to work for projects that need idea generation and technology applications as per organization needs and priorities.
• Worked in portfolios like centralized regulatory query handling and expertise in approval process.
• Proven abilities in trouble shooting and scaling up of developed dosage forms across manufacturing locations
• Handled leadership role in process development, technology transfer to commercial scale for teams and associates in manufacturing set ups for different manufacturing units
• Handled and had practical exposure in international client projects with development to commercialization discussions and interactions, in license activities and site transfer related coordination and includes contract research and contract manufacturing activities.
• Planning and aptly extension of projects to other regulated markets like Brazil, South Africa, Canada for different oral dosage forms.
• Proven abilities in drug product selection and identification for core markets like North America and also on the R&D administration, up gradation and future expansion needs.
• Key area of interest include identification of project needs, project tracking and summarizing the priority of critical and non critical projects on organization front and had involved in business development activities including in licensing approaches.

• Empowering and inclusive leadership with focus elements of active coaching and mentoring direct associates and teams. Creating competitiveness environment for achieving and sustaining organizational goals
• Diversity as top focus with top driven across the teams that is inclusive of resources, skillsets, abilities and encouraging equal opportunity environment
• Driving inspiration as prime enabler to associates through development, growth opportunities and skill enhancement
• Motivating teams and individuals on situational ad collaborative way of working
• Inquisitive mindset with focus on generic drug development which is simple, pragmatic and quick decision making with calculated and smart risks
• Inspiring work environments and culture that is inclusive of feedback, self-awareness and inward looking practices
• Transparency, openness and empathy aiming at valuing human relations at professional work place which fosters better productive outcomes
• Safe working environment objective along with quality cultures and compliance to organizational norms at all times
• Reward and recognition atmosphere periodically that fosters an atmosphere of doing better and best with focus on excellence in multiple work domains
• Building teams with individuals who demonstrate leadership and drive independently with innovation mindset along with full potential

• Sr.GM, Intas Pharmaceuticals Ltd., Ahmedabad, 06/2010, 2016, Leading at senior leadership role handling different teams as per project(s) allocation for different markets, Identification of project needs for the entire cycle of development to commercialization, Allocation of resources as per project needs and priorities, Team building and restructuring from time to time, Strategizing of projects, identification of markets, Project tracking, management, risk assessment and contingency plans, Sensizing cross functional teams and aligning their priorities, Strategy building, patent landscape, development methodology, business case, project cost for each project, Cross functional motivation and interactions at periodic intervals, Department budgetary plans, equipment up gradation, system improvement, technology transfer, documentation, training needs at large during the entire cycle of product development, Understanding regulatory requirements and complications and translating the risk involved from time to time
• Manager, Dr. Reddy’s Laboratories Ltd., Hyderabad, 2002, 06/2010, Leading at junior management roles with team of scientists for five to six projects, Responsible for leading the team, designing the experiments, monitoring the experimental trials & review the analytical reports., Technical strategy and path for the projects from development to scale up operations, Supporting regulatory queries for the projects allocated and helping department needs, Patent landscape and development of non infringing strategies, Development of different in vitro techniques if required for better in vivo success and achieving bioequivalence in short span, Documentation support including Qualification trial reports, Stability results compilation, Master Manufacturing Record (MMR), Process Validation Protocol (PVP), Batch Manufacturing Record (BMR), Hold Study Protocols, Sampling protocols and Stability protocols, Product development report (PDR).
• Research Scientist, Panacea Biotec Ltd., Punjab, 1999, 2002, Execution of experimental and exploratory development trials as per identified strategy at bench level as an individual contributor, Optimization of experiments, documentation, procurement and technology transfer support, Identification of different approaches and highlighting the advantages for different dosage forms for domestic market, Involvement in department SOP's and adapting in working with different team members, Coordination with different departments respective to product needs, Conducting Pre-formulation studies, Designing of Prototype formula, Optimization and finalization of Formula composition and Manufacturing process., Involving in activities related to technology transfer and execution of scale up batches, Stability results compilation & documentation preparation

• Core team in-charge and responsible for design, planning and organizing scientific sessions during Indian Pharmaceutical Congress (IPC), 2004, Kolkata and consecutively for the next calendar years
• Writing skills established through publication of Diploma guide papers for Diploma students with Vijaya Publishers.
• Designed practical syllabus for M. Pharm, Pharmaceutics curriculum in Kakatiya University and also initiated several documentation practices.
• Had a strong inclination and passion with strong leadership abilities and played key role in organizing seminars, events, and excursions during academic days.
• Life membership with Indian Pharmaceutical Association (IPA).
• Delivered and participated as a key speaker in several symposiums organized by leading Pharmacy institutions.
• Key panel member of Ph. D thesis and examination for Pharmaceutics specialization in Nirma college of Pharmacy, Nirma University, Ahmedabad.
• Guided various students in identifying post graduate project selection, tracking and till submission of thesis during the professional career.

• Age: 45 years
• Number of Children: Two daughters and school going
• Marital Status: Married

• Research Paper titled "Nanosuspensions of Albendazole for improvement of solubility and oral bioavailability", M. Pavan Kumar, S. S. Apte & Y. Madhusudan Rao, presented in 56th IPC, Kolkata.
• Survey on marketed controlled release preparations, M. Pavan Kumar, A. Laxmi Narayana, B. Sreedhar, V. Vijay Kumar & Y. Madhusudan Rao, presented in 56th IPC, Kolkata.
• Herbal formulations - A comprehensive survey , M. Pavan Kumar, S. Ramesh, G. Y. Sravan, V. Srikanth, V. Vinay Kumar & Y. Madhusudan Rao, presented in 56th IPC, Kolkata.
• Monolithic osmotic tablet of diclofenac sodium using PEG-6000 as osmogen, V. Rajesh, T. Ashok, M. Pavan Kumar, Mrs. Shyeda and Y. Madhusudan Rao, presented in 56th IPC, Kolkata.
• Career scenario for pharmaceutics specialization - An analysis, M. Pavan Kumar, T. Ashok, K. Chandrasekhar & Y. Madhusudan Rao, presented in 55th IPC, Chennai.
• Comparative in vitro performance evaluation of liposomal miconazole nitrate cream, M. Pavan Kumar, A. N. Misra, presented in 50th IPC , Mumbai.
• VAT – A boon or bane to pharmaceutical Industry? – A Market Survey, M. Pavan Kumar, K. Hari Nath, M. Srikanth, Y. Madhusudan Rao, presented in 57th IPC, Hyderabad.
• Process analytical technology (PAT) initiatives in Indian Pharmaceutical Industry – An investigation, M. Pavan Kumar, B. Sreedhar, Y. Madhusudan Rao & Dr. S. S. Apte, presented in 57th IPC, Hyderabad.
• A market survey on Insulin medication, M. Pavan Kumar, D. Adukondalu , C. Anil Kumar, V. Rajesh & Y. Madhusudan Rao, presented in 57th IPC, Hyderabad
• Barriers to Academic - Industry Collaboration - An investigation, M. Pavan Kumar, G. Y. Srawan Kumar, Y. Madhusudan Rao, presented in 57th IPC, Hyderabad.
• Preparation of Albendazole tablets with enhanced dissolution, V. Kiran Kumar, M. Pavan Kumar, J. Baweja & Y. Madhusudan Rao, presented in 57th IPC, Hyderabad.
• Research Paper titled “Pharmacokinetic studies on controlled release dosage form of Nimesulide in fed and fasted states” poster presented in CRS Annual meeting at Ooty in 2000.
• M. Pavan Kumar, Sarabjit Singh, Sukhjeet Singh “Pharmacokinetic studies on controlled release dosage form of nimesulide in fed and fasted states” Indian Journal of Pharmaceutical Sciences, May 2002.
• M. Pavan Kumar, S. S. Apte & Y. Madhusudan Rao “Formulation of Nanosuspensions of Albendazole for Oral Administration” Current Nanoscience, 2008, 4, 53-58.
• M. Pavan Kumar, S. S. Apte & Y. Madhusudan Rao “Improved Bioavailability of Albendazole following oral administration of nanosuspension in rats” Current Nanoscience, 2007, 3, 191-194.
• M. Pavan Kumar, Bandari Suresh, S.S.Q. Hussaini, Y. Madhusudan Rao and Shashank Apte “ Comparative in vitro study of six carbamazepine products” AAPS PharmSciTech., 2008, 9, 357-365.
• M. Pavan Kumar, G. Y. Srawan, S.S. Apte & Y. Madhusudan Rao “A review on solubilization techniques for poorly water soluble drug” PDA journal of Pharm. Sci., 2010.
• M. Pavan Kumar, S.S. Apte & Y. Madhusudan Rao “Improved bioavailability of albendazole in rats after oral administration of nanosuspension” presented at Controlled Release Society Annual meeting held in Austria on July 22 –26, 2006.
• M. Pavan Kumar, S.S. Apte & Y. Madhusudan Rao “Colloidal Systems of Carbamazepine with enhanced oral bioavailability” AAPS annual meeting, 2006, Texas, USA.
• Useni Reddy Mallu, Arunkanth Krishnakumar Nair, Hanimi Reddy Bapatu, Pavan Kumar M et al., "API Supplier Change or Addition of Alternate API Supplier in Generic Drug Products: Cost, Quality and Regulatory Factors" Phamaceutica Analytica Acta, 2015, Vol 6, Issue 5.
• Useni Reddy Mallu, Arunkanth Krishnakumar Nair, Hanimi Reddy Bapatu, Pavan Kumar M et al., "Impact of API (Active Pharmaceutical Ingredient) Source Selection on Generic Drug Products" Pharmaceutical Regulatory Affairs, 2015, Vol 4, Issue 2.